SAB Biotherapeutics (SABS) Other Gross PP&E Adjustments (2020 - 2025)
Historic Other Gross PP&E Adjustments for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $26.4 million.
- SAB Biotherapeutics' Other Gross PP&E Adjustments rose 36.49% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year increase of 36.49%. This contributed to the annual value of $23.4 million for FY2024, which is 93.7% down from last year.
- Latest data reveals that SAB Biotherapeutics reported Other Gross PP&E Adjustments of $26.4 million as of Q3 2025, which was up 36.49% from $26.4 million recorded in Q2 2025.
- Over the past 5 years, SAB Biotherapeutics' Other Gross PP&E Adjustments peaked at $26.4 million during Q3 2025, and registered a low of -$1.4 million during Q4 2021.
- In the last 5 years, SAB Biotherapeutics' Other Gross PP&E Adjustments had a median value of $25.5 million in 2022 and averaged $21.1 million.
- As far as peak fluctuations go, SAB Biotherapeutics' Other Gross PP&E Adjustments tumbled by 17336.36% in 2021, and later surged by 175016.94% in 2022.
- SAB Biotherapeutics' Other Gross PP&E Adjustments (Quarter) stood at -$1.4 million in 2021, then surged by 1750.17% to $23.5 million in 2022, then rose by 0.54% to $23.7 million in 2023, then decreased by 0.94% to $23.4 million in 2024, then increased by 12.66% to $26.4 million in 2025.
- Its Other Gross PP&E Adjustments was $26.4 million in Q3 2025, compared to $26.4 million in Q2 2025 and $26.4 million in Q1 2025.